Zurich-based Bellevue Group has named a new member to its board of directors to replace a long-serving member.
Barbara Angehrn Pavik will be proposed as a new member of the Bellevue Group board of directors at its annual general meeting (AGM) on March 21, according to a statement from the company on Wednesday.
She replaces Daniel Sigg who after 16 years as a board member will not stand for re-election at the AGM, as previously announced.
She brings extensive pharma experience to Bellevue, having held various management positions in the international healthcare industry, most recently as a chief business officer and member of the executive committee at Vifor Parma Group.
International Experience
Before her four-year tenure there, she was the founder and CEO of Stepstone Pharma and held senior positions at Exelixis Pharmaceuticals International in San Francisco, Onyx Pharmaceuticals International, and Amgen International, both based in Zug. She has served on Medmix's board of directors since 2022.
Bellevue Chairman Veit de Maddalena said of Pavik's appointment that «we are very pleased that Barbara Angehrn Pavik will further strengthen the expertise of Bellevue's Board of Directors. Thanks to her many years of international experience, she will be able to provide additional impetus to our Group, which specializes in healthcare strategies, over the coming years.»
Bellevue will release its annual report for 2022 on February 28. In January it warned that it expects with net profit expected to fall 42 percent to 25 million Swiss francs ($27.1 million), after record profits the year before.
It has already announced it will propose an ordinary dividend of two Swiss francs at the AGM, as finews.com reported.
